Staci Rice, 40, started taking semaglutide on May 4 2022 after trying "every diet around," she said
A separate 12-week trial at 30mg showed an average loss of 8.1 kilograms, with 95.8 percent of participants achieving at least 5 percent body weight loss
Known also by its brand name Zepbound, tirzepatide is an FDA-approved dual-action GLP-1 and GIP receptor agonist that offers comprehensive benefits for weight management
Use reminders or tools to help maintain your weekly schedule
These medications should also be avoided in patients with a history of acute or chronic pancreatitis, which is a painful and potentially fatal inflammation of the pancreas
So, it's clear that we should take the weight-loss benefit claims of these supplements with a pinch of salt, but is there a place for them in the treatment of insulin-sensitive conditions such as PCOS and pre-diabetes